People's Justice

Who qualifies

Past Zantac use: what needs a claim review?

A lawyer must check the actual medicine, cancer diagnosis, proof and court path. This page sets no minimum use period or rule that a firm will accept your claim.

See If You Qualify

Free · No obligation · About 2 minutes

Updated Oct 4, 202613 sources

This may apply to you if

  • Preparation suggestions only; no cancer list, use-duration threshold or current firm acceptance rule is verified.
  • Describe the product, dates and diagnosis you want checked.
  • Ask a lawyer what evidence and court route apply to your own situation.

What the public record says

These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.

Francis J. Jones, Jr. · Superior Court of the State of Delaware · Superior Court judge signing the cited order

Finding: The April order grants judgment for defendants for consolidated complaints filed on or before December 1, 2025; later-filed evidence is addressed separately.

Jones: April14,2026 Delaware Zantac order (opens in a new tab) · Apr 14, 2026 · Checked Oct 4, 2026

The evidence and its limits

Yonsei University College of Medicine, first-author affiliation · JAMA Network Open · 2023

Ranitidine Use and Incident Cancer in a Multinational Cohort

Design:
Cohort
Participants:
1,183,999 eligible people across eleven analytical databases: 909,168 new ranitidine users and 274,831 other H2-blocker users. Primary meta-analysis used four databases meeting stricter balance criteria.
Finding:
The primary and broader comparisons did not show a statistically significant overall cancer increase relative to other H2 blockers.
Main limitation
Prescription or dispensing data do not capture all actual or nonprescription use; individual impurity and dietary exposure were not measured. Follow-up may miss long-latency effects and rare or small differences. The paper reports distinct primary, broader and calibrated estimates; no pooled number is presented as one universal eleven-database result. No individual cause or universal safety finding.

Read the source: Ranitidine Use and Incident Cancer in a Multinational Cohort (opens in a new tab) · Checked Oct 4, 2026

Tainan Municipal Hospital, first-author affiliation · International Journal of Environmental Research and Public Health · 2022

Pharmacoepidemiological research on NDMA-contaminated ranitidine use and long-term cancer risk

Design:
Cohort
Participants:
55,110 ranitidine users and 55,110 matched untreated people; additional drug-comparison analyses are separate.
Finding:
Several cancer rates were higher in the ranitidine group compared with untreated controls.
Main limitation
Observational matching cannot balance unknown factors. Personal impurity, smoking, alcohol and complete actual use were unavailable. Authors declared no conflicts and no funder role; that is not a review or endorsement of PJ.

Read the source: Pharmacoepidemiological research on NDMA-contaminated ranitidine use and long-term cancer risk (opens in a new tab) · Checked Oct 4, 2026

The short answer

Who can ask for a past-use claim review?
If you think an older drug harmed you, ask a lawyer for a check. Taking ranitidine alone does not prove cause or that you have a case. [4]
What does not prove a claim or makes it harder?
A brand name or cancer diagnosis does not prove the claim. A lawyer needs to check the product, science and actual court path. [6]
What if I used a generic or a newer Zantac product?
Check the drug and its maker with a lawyer or pharmacist. The Zantac 360 label names a different drug, famotidine. It is not ranitidine. [13]
What records help and how do I obtain them?
Keep the cancer, care, medicine and earlier case papers you have. Ask providers for missing covered copies. Mark dates you are not sure about. [3]

The process

What happens next

  1. 01

    You answer a few questions

    About two minutes. Nothing is sent until you agree on the last step and press submit.

  2. 02

    A lawyer looks at it

    A lawyer at the firm reads your answers and checks them against the current case criteria.

  3. 03

    The firm decides and gets in touch

    If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.

The criteria attorneys check

  1. 01

    Preparation suggestions only; no cancer list, use-duration threshold or current firm acceptance rule is verified.

  2. 02

    Describe the product, dates and diagnosis you want checked.

  3. 03

    Ask a lawyer what evidence and court route apply to your own situation.

Who can ask for a past-use claim review?

If you think an older drug harmed you, ask a lawyer for a check. Taking ranitidine alone does not prove cause or that you have a case.

FDA’s 2020 withdrawal concerns then-marketed products and a chemical impurity. It does not prove what was in your tablets or that your cancer came from the drug. Bring the history you know.

What does not prove a claim or makes it harder?

A brand name or cancer diagnosis does not prove the claim. A lawyer needs to check the product, science and actual court path.

The 2023 comparison found no clear overall rise against other acid drugs; the 2022 study found positive links for several cancers. Neither supplies a firm’s minimum use rule or proves individual cause.

What if I used a generic or a newer Zantac product?

Check the ingredient and maker with a lawyer or pharmacist. The Zantac 360 label names a different drug, famotidine. It is not ranitidine.

Do not infer an old purchase from a brand name alone. The product label helps identify the medicine, but it does not establish which legal claim or company can be pursued.

What records help and how do I obtain them?

Keep the cancer, care, medicine and earlier case papers you have. Ask providers for missing covered copies. Mark dates you are not sure about.

List approximate use dates as approximate. Covered health-record access has exceptions, and a helper may need authority. Missing paperwork is a question for review, not a reason to invent a duration or purchase.

Is there a deadline for my claim?

A lawyer must check the claim and applicable law. There is no single national Zantac filing date supplied by this page.

Delaware’s April order uses an existing-case filing boundary for its evidence ruling. That date does not replace your own time-limit assessment or promise a new available court route.

What happens next when I seek a review?

Ask who will check your product, proof and court options. A contact request is not a filed case or a promise of acceptance.

Give the lawyer any prior lawsuit or agreement. Delaware’s dated ruling is not a current firm intake rule, and neither original study awards money. Ask what further facts are needed before relying on a proposed next step.

Find out where you stand.

The review is free and private. Asking for it doesn’t commit you to anything.

Register your interest

Sources

  1. ABA Model Rule 1.5: feesABA Model Rule 1.5: fees
  2. Southern District of New York: time limitsSouthern District of New York: time limits · court
  3. 45 CFR 164.524: access to health records45 CFR 164.524: access to health records · regulator
  4. FDA: April2020 ranitidine withdrawal requestFDA: April2020 ranitidine withdrawal request · regulator
  5. FDA: reformulated ranitidine approvalFDA: reformulated ranitidine approval · regulator
  6. You: original multinational ranitidine cancer cohortYou: original multinational ranitidine cancer cohort · study
  7. Wang: original Taiwan ranitidine cohortWang: original Taiwan ranitidine cohort · study
  8. Jones: April14,2026 Delaware Zantac orderJones: April14,2026 Delaware Zantac order · court
  9. Jones: January29,2026 Delaware time-limit rulingJones: January29,2026 Delaware time-limit ruling · court
  10. GSK announced agreements with 10 plaintiff firms representing ~80,000 claimants (93% of pending US state-court Zantac cases) to pay up to $2.2 billion in aggregate, with full implementation expected by end of H1 2025; GSK admitted no liability. GSK also agreed to pay $70 million to resolve the Valisure qui tam complaint. Verified from GSK's own press statement.us.gsk.com · Oct 9, 2024
  11. Sanofi agreed to pay more than $100 million to settle ~4,000 Zantac cancer suits in state courts outside Delaware — the first major resolution in the litigation, averaging more than $25,000 per claim per Bloomberg's reporting (republished by Insurance Journal, Apr 23, 2024; deal announced earlier that month). Sanofi denied liability; 70,000+ suits then remained, mostly in Delaware.insurancejournal.com · Apr 23, 2024 · study
  12. MDL 2924 (S.D. Fla., Judge Robin L. Rosenberg) omnibus Daubert order (Doc 6120, 341 pages): ALL defendants' Daubert motions on general causation GRANTED and defendants' summary judgment motion GRANTED — plaintiffs 'fail to produce admissible primary evidence of general causation' that ranitidine causes cancer, ending the federal MDL claims. Verified from the court order itself.gsk.com · Dec 6, 2022 · court
  13. DailyMed: Zantac 360 famotidine label

Checked against 10 primary sources by People's Justice editors · Updated

How we make money

People's Justice research team · Updated Oct 4, 2026